Michael Gordon

Chief Medical Officer

University Name

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

40%

Pharmacology

30%

Drug Development

30%

Targeted Therapy

30%

Neoadjuvant Therapy

20%

Immunotherapy

20%

Oncology

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles4

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Article Link

Year:

2022

Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Results From a Phase 1b Trial

Article Link

Year:

2022

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors

Article Link

Year:

2021

Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma

Article Link

Year:

2020

Collaborators2

Yung-Jue Bang

Professor

Seoul National University College of Medicine

SOUTH KOREA

Ahmad Awada

Université libre de Bruxelles (ULB)

BELGIUM

How do I reach out?

Meet Kite AI